Wall Street analysts predict that CytomX Therapeutics Inc (NASDAQ:CTMX) will announce sales of $10.70 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for CytomX Therapeutics’ earnings. The lowest sales estimate is $600,000.00 and the highest is $16.50 million. CytomX Therapeutics reported sales of $6.27 million during the same quarter last year, which would suggest a positive year over year growth rate of 70.7%. The business is expected to announce its next earnings results on Thursday, March 1st.
On average, analysts expect that CytomX Therapeutics will report full-year sales of $10.70 million for the current fiscal year, with estimates ranging from $45.20 million to $61.00 million. For the next fiscal year, analysts forecast that the company will post sales of $79.53 million per share, with estimates ranging from $60.00 million to $104.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover CytomX Therapeutics.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.14). CytomX Therapeutics had a negative net margin of 113.64% and a negative return on equity of 92.42%.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 14,340 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.60, for a total transaction of $295,404.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.58, for a total transaction of $51,450.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,466 shares of company stock valued at $1,267,014. 8.00% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in CTMX. New York State Common Retirement Fund grew its stake in shares of CytomX Therapeutics by 48.8% during the 2nd quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 10,199 shares during the period. Trexquant Investment LP acquired a new position in shares of CytomX Therapeutics during the 3rd quarter worth $474,000. California State Teachers Retirement System grew its stake in shares of CytomX Therapeutics by 27.8% during the 2nd quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock worth $797,000 after purchasing an additional 11,200 shares during the period. Hamilton Lane Advisors LLC grew its stake in shares of CytomX Therapeutics by 77.8% during the 4th quarter. Hamilton Lane Advisors LLC now owns 50,394 shares of the biotechnology company’s stock worth $1,064,000 after purchasing an additional 22,048 shares during the period. Finally, TIAA CREF Investment Management LLC grew its stake in shares of CytomX Therapeutics by 183.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock worth $2,628,000 after purchasing an additional 109,791 shares during the period. Institutional investors own 63.15% of the company’s stock.
CytomX Therapeutics (NASDAQ CTMX) opened at $26.74 on Tuesday. CytomX Therapeutics has a twelve month low of $11.12 and a twelve month high of $28.05. The stock has a market cap of $1,030.00 and a price-to-earnings ratio of -17.03.
WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/06/10-70-million-in-sales-expected-for-cytomx-therapeutics-inc-ctmx-this-quarter.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.